Recent News

• 03.10.2025 - 2025 Leerink Partners Global Healthcare Conference
• 03.10.2025 - 2025 Leerink Partners Global Healthcare Conference
• 03.07.2025 - Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
• 03.07.2025 - Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.28.2025 - Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
• 02.28.2025 - Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

Recent Filings

• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 144 Report of proposed sale of securities
• 03.03.2025 - 144 Report of proposed sale of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities